Throughout our 130-year history, we have focused on developing medicines that effectively restore, restart and regulate fundamental female and male body processes. From our initial tonic wine to homeopathic, orally delivered remedies for a variety of respiratory, cardiovascular, anti-inflammatory conditions to our current pipeline of hormone-replacement therapies, Besins has built an impressive track record of innovation through cutting-edge research and progressive partnership.
We developed transdermal gel technology, a novel drug-delivery mechanism, with several benefits over transdermal patches. Besins was the first company to successfully commercialize this technology with the introduction of Progestogel® and Oestrogel®. With the introduction of Utrogestan®, we became a world leader in bioavailable, orally administered natural progesterone treatments. We pioneered micronized progesterone firstly as an oral formulation then extended into vaginal administration for a host of women’s health indications. Another development included the world’s first dihydrotestosterone (DHT) treatment for andropause and gynecomastia.
Today, our discovery and development efforts are focused on gynecology, fertility, obstetrical conditions and androgen deficiency — a core set of therapeutic areas where we have proven expertise. Besins is actively supporting more than 40 investigator-initiated trials
Besins Healthcare global research and development is conducted out of Besins healthcare Ireland , which focuses on unmet medical needs. Advancing medical science and improving clinical patient outcomes are two goals and drivers for our company, & our employees as we enter our next era of innovation.
|Product Candidates||Proof of Concept||Phase 1/2||Phase 3|
Copyright © 2018 Besins Healthcare. All Rights Reserved.